WallStSmart
ACLX

Arcellx Inc

NASDAQ: ACLX · HEALTHCARE · BIOTECHNOLOGY

$115.07
+0.00% today

Updated 2026-04-28

Market cap
$6.73B
P/E ratio
P/S ratio
302.04x
EPS (TTM)
$-4.07
Dividend yield
52W range
$48 – $115
Volume
2.8M

Arcellx Inc (ACLX) Financial statements

SEC filings — annual and quarterly data.

Profit margin
-1,027.25%
Operating margin
-1,135.61%
ROE
-53.40%
ROA
-24.00%
Debt/equity

Margin trends — annual

Gross margin Operating margin Profit margin
YearRevenueNet incomeGross marginOp. marginProfit margin
2018$-8.31M
2019$0.00$-17.97M
2020$0.00$-32.09M
2021$0.00$-63.93M
2022$17.91M$-188.68M-12.42%-1,067.77%-1,053.37%
2023$110.32M$-70.69M100.00%-81.47%-64.08%
2024$107.94M$-107.35M95.19%-127.46%-99.46%
2025$22.29M$-228.93M70.03%-1,135.61%-1,027.25%

Frequently asked questions

What is Arcellx Inc's revenue?

Arcellx Inc's trailing twelve-month revenue is $22.29M. Revenue is the top line the whole model builds on, and at this scale the question shifts from how fast it grows to whether margins hold as it compounds.

How profitable is ACLX?

In its most recent fiscal year, ACLX ran a gross margin of 70.03%, an operating margin of -1,135.61%, and a net margin of -1,027.25%. Margins this high mean most of each extra dollar of revenue drops through to profit, which is the signature of real pricing power.

How much free cash flow does ACLX generate?

ACLX produced $-212.59M in free cash flow in its most recent fiscal year. Free cash flow is what is left after running and reinvesting in the business, and it is the cash that actually funds buybacks, dividends, and a stronger balance sheet.